Ready-to-use AAV1 particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR1-FusionRed (#105678). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR1-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV Retrograde particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV Retrograde particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV9 particles produced from pAAV-EF1a-DIO-ChrimsonR-mRuby2-KV2.1-WPRE-SV40 (#124603). In addition to the viral particles, you will also receive purified pAAV-EF1a-DIO-ChrimsonR-mRuby2-KV2.1-WPRE-SV40 plasmid DNA. EF1a-driven, Cre-dependent expression of ChrimsonR fused to mRuby2 fluorophore and targeted to neuronal soma for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from AAV-hSyn-Ribo-jGCaMP8m (#167574). In addition to the viral particles, you will also receive purified AAV-hSyn-Ribo-jGCaMP8m plasmid DNA. Synapsin-driven neuronal expression of soma-targeted (RL-10, ribosomal tag) jGCaMP8m. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from AAV-hSyn-Ribo-jGCaMP8s (#167572). In addition to the viral particles, you will also receive purified AAV-hSyn-Ribo-jGCaMP8s plasmid DNA. Synapsin-driven neuronal expression of soma-targeted (RL-10, ribosomal tag) jGCaMP8s. These AAV preparations are suitable purity for injection into animals.

Expresses the fluorescent protein pH sensor pHlorin2 in the glycosomes of Trypanosomal brucei

Mammalian expression vector with myc-tagged mouse Grhl3 coding sequence

Ready-to-use AAV9 particles produced from pAAV-CAG-DIO-NLS-mRuby3-IRES-eGtACR1-ST (#109048). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-NLS-mRuby3-IRES-eGtACR1-ST plasmid DNA. Cre-dependent expression of the anion channelrhodopsin GtACR1 fused to ER export signal and targeted to the neuronal soma and proximal dendrites, translated from an internal ribosomal entry site (IRES) following mRuby3 expression. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV5 particles produced from pAAV-FLEX-EGFPL10a (#98747). In addition to the viral particles, you will also receive purified pAAV-FLEX-EGFPL10a plasmid DNA. Cre-dependent EGFPL10a (EGFP-tagged ribosomal protein) expression for translating ribosome affinity purification (TRAP). These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV Retrograde particles produced from pAAV-FLEX-EGFPL10a (#98747). In addition to the viral particles, you will also receive purified pAAV-FLEX-EGFPL10a plasmid DNA. Cre-dependent EGFPL10a (EGFP-tagged ribosomal protein) expression for translating ribosome affinity purification (TRAP). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV9 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

Lentiviral expression of a peroxisomal eGFP